
Erwin L Roggen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6879674/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	iPSC-derived cortical neurons to study sporadic Alzheimer disease: A transcriptome comparison with post-mortem brain samples. Toxicology Letters, 2022, 356, 89-99.	0.8	8
2	Sporadic Alzheimer's Disease- and Neurotoxicity-Related microRNAs Affecting Key Events of Tau-Driven Adverse Outcome Pathway Toward Memory Loss. Journal of Alzheimer's Disease, 2022, 86, 1427-1457.	2.6	4
3	Building a Network of Adverse Outcome Pathways (AOPs) Incorporating the Tau-Driven AOP Toward Memory Loss (AOP429). Journal of Alzheimer's Disease Reports, 2022, 6, 271-296.	2.2	4
4	A Tau-Driven Adverse Outcome Pathway Blueprint Toward Memory Loss in Sporadic (Late-Onset) Alzheimer's Disease with Plausible Molecular Initiating Event Plug-Ins for Environmental Neurotoxicants. Journal of Alzheimer's Disease, 2021, 81, 459-485.	2.6	8
5	Validation of the GARDâ,,¢skin Assay for Assessment of Chemical Skin Sensitizers: Ring Trial Results of Predictive Performance and Reproducibility. Toxicological Sciences, 2019, 170, 374-381.	3.1	24
6	Applying the adverse outcome pathway (AOP) for food sensitization to support in vitro testing strategies. Trends in Food Science and Technology, 2019, 85, 307-319.	15.1	16
7	An alternative biomarker-based approach for the prediction of proteins known to sensitize the respiratory tract. Toxicology in Vitro, 2018, 46, 155-162.	2.4	2
8	The validation of GARDskin. Toxicology Letters, 2018, 295, S229.	0.8	0
9	Development of an in vitro method to estimate the sensitization induction level of contact allergens. Toxicology Letters, 2017, 271, 1-11.	0.8	26
10	An Adverse Outcome Pathway for Sensitization of the Respiratory Tract by Low-Molecular-Weight Chemicals: Building Evidence to Support the Utility of <i>In Vitro</i> and <i>In Silico</i> Methods in a Regulatory Context. Applied in Vitro Toxicology, 2017, 3, 213-226.	1.1	46
11	Overview of inÂvitro assessment of immunotoxicity. Current Opinion in Toxicology, 2017, 5, 13-18.	5.0	11
12	Application of the adverse outcome pathway (AOP) concept to structure the available in vivo and in vitro mechanistic data for allergic sensitization to food proteins. Clinical and Translational Allergy, 2017, 7, 13.	3.2	39
13	Preliminary performance data of the <scp>RHE</scp> / <scp>IL</scp> â€18 assay performed on SkinEthic ^{â,,¢} <scp>RHE</scp> for the identification of contact sensitizers. International Journal of Cosmetic Science, 2017, 39, 121-132.	2.6	10
14	Advances in the development of in vitro airway models as innovative tools to identify chemical respiratory sensitizers. Toxicology Letters, 2017, 280, S61.	0.8	0
15	Overview on Current Status and Combination of Test Methods. , 2017, , 199-214.		0
16	Alternative Approach for Potency Assessment: In Vitro Methods. Cosmetics, 2016, 3, 7.	3.3	7
17	The importance of the undescribed for industrial and regulatory application of animal-free methods for safety assessment. Toxicology Letters, 2015, 238, S2-S3.	0.8	0
18	In silico tools for exploring potential human allergy to proteins. Drug Discovery Today: Disease Models, 2015, 17-18, 3-11.	1.2	13

ERWIN L ROGGEN

#	Article	IF	CITATIONS
19	Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology. ALTEX: Alternatives To Animal Experimentation, 2015, 32, 327-378.	1.5	108
20	Safety Evaluation of Cosmetic Ingredients: In Vitro Opportunities for the Identification of Contact Allergens. Cosmetics, 2014, 1, 61-74.	3.3	13
21	Immunotoxicity Testing. , 2014, , 57-65.		1
22	<i>In Vitro</i> Approaches for Detection of Chemical Sensitization. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 32-40.	2.5	26
23	Allergic sensitization: screening methods. Clinical and Translational Allergy, 2014, 4, 13.	3.2	34
24	lgE versus lgG4 epitopes of the peanut allergen Ara h 1 in patients with severe allergy. Molecular Immunology, 2014, 58, 169-176.	2.2	21
25	Treatment of both native and deamidated gluten peptides with an endo-peptidase from Aspergillus niger prevents stimulation of gut-derived gluten-reactive T cells from either children or adults with celiac disease. Clinical Immunology, 2014, 153, 323-331.	3.2	10
26	International ring trial of the epidermal equivalent sensitizer potency assay: reproducibility and predictive capacity. ALTEX: Alternatives To Animal Experimentation, 2014, 31, 251-268.	1.5	19
27	Potential of in vitro reconstituted 3D human airway epithelia (MucilAirâ,,¢) to assess respiratory sensitizers. Toxicology in Vitro, 2013, 27, 1151-1156.	2.4	75
28	Transfer of a two-tiered keratinocyte assay: IL-18 production by NCTC2544 to determine the skin sensitizing capacity and epidermal equivalent assay to determine sensitizer potency. Toxicology in Vitro, 2013, 27, 1135-1150.	2.4	39
29	An epidermal equivalent assay for identification and ranking potency of contact sensitizers. Toxicology and Applied Pharmacology, 2013, 272, 529-541.	2.8	99
30	Application of the acquired knowledge and implementation of the Sens-it-iv toolbox for identification and classification of skin and respiratory sensitizers. Toxicology in Vitro, 2013, 27, 1122-1126.	2.4	7
31	Sens-it-iv: A European Union project to develop novel tools for the identification of skin and respiratory sensitizers. Toxicology in Vitro, 2013, 27, 1121.	2.4	2
32	Advanced tests for skin and respiratory sensitization assessment. ALTEX: Alternatives To Animal Experimentation, 2013, 30, 231-252.	1.5	17
33	Implementation challenges for designing Integrated In Vitro Testing Strategies (ITS) aiming at reducing and replacing animal experimentation. Toxicology in Vitro, 2012, 26, 526-534.	2.4	20
34	lgE epitopes of intact and digested Ara h 1: A comparative study in humans and rats. Molecular Immunology, 2012, 51, 337-346.	2.2	26
35	A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing. ALTEX: Alternatives To Animal Experimentation, 2012, 29, 3-91.	1.5	190
36	Toxicology in the 21st century – Working our way towards a visionary reality. Toxicology in Vitro, 2011, 25, 874-881.	2.4	50

ERWIN L ROGGEN

#	Article	IF	CITATIONS
37	In vitro Toxicity Testing in the Twenty-First Century. Frontiers in Pharmacology, 2011, 2, 3.	3.5	20
38	An expert consortium review of the EC-commissioned report "Alternative (Non-Animal) Methods for Cosmetics Testing: Current Status and Future Prospects – 2010― ALTEX: Alternatives To Animal Experimentation, 2011, 28, 183-209.	1.5	37
39	Immunotoxicology: Opportunities for Non-animal Test Development. ATLA Alternatives To Laboratory Animals, 2009, 37, 387-397.	1.0	44
40	Safe cosmetics without animal testing? Contributions of the EU Project Sens-it-iv. Journal Fur Verbraucherschutz Und Lebensmittelsicherheit, 2009, 4, 41-48.	1.4	8
41	B-cell epitope engineering: A matter of recognizing protein features and motives. Drug Discovery Today: Technologies, 2008, 5, e49-e55.	4.0	8
42	Models for Prediction of Immunogenicity. , 2008, , 75-95.		4
43	Sens-it-iv: New approaches to the assessment of respiratory sensitisation potential. Toxicology Letters, 2007, 172, S7.	0.8	0
44	Management of an Integrated Project (Sens-it-iv) to Develop In Vitro Tests to Assess Sensitisation. ATLA Alternatives To Laboratory Animals, 2007, 35, 317-322.	1.0	16
45	Skin Sensitisation and Epidermal Disposition: The Relevance of Epidermal Disposition for Sensitisation Hazard Identification and Risk Assessment. ATLA Alternatives To Laboratory Animals, 2007, 35, 137-154.	1.0	69
46	Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. Journal of Molecular Recognition, 2007, 20, 75-82.	2.1	209
47	Interactions between dendritic cells and epithelial cells in allergic disease. Toxicology Letters, 2006, 162, 71-82.	0.8	21
48	Investigation on possible allergenicity of 19 different commercial enzymes used in the food industry. Food and Chemical Toxicology, 2006, 44, 1909-1915.	3.6	34
49	A novel approach for investigation of specific and cross-reactive IgE epitopes on Bet v 1 and homologous food allergens in individual patients. Molecular Immunology, 2006, 43, 268-278.	2.2	68
50	Respiratory immunotoxicity: An in vitro assessment. Toxicology in Vitro, 2006, 20, 1249-1264.	2.4	65
51	An <i>in silico</i> method using an epitope motif database for predicting the location of antigenic determinants on proteins in a structural context. Journal of Molecular Recognition, 2006, 19, 21-29.	2.1	29
52	Recent Developments with B-Cell Epitope Identification for Predictive Studies. Journal of Immunotoxicology, 2006, 3, 137-149.	1.7	36
53	Isolation of high-affinity human IgE and IgG antibodies recognising Bet v 1 and Humicola lanuginosa lipase from combinatorial phage libraries. Molecular Immunology, 2004, 41, 941-953.	2.2	33